Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

A legfontosabb adatok

Ki végzi
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
105 fő, tervezett
Kezdés
2026. jún. 21.
Várható befejezés
2027. júl. 15.
A vizsgálat típusa
Megfigyeléses, 3 csoport
A regiszteradat frissítve
2026. október 27.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults in intensive care, with or without sepsis (a severe body reaction to infection), and healthy volunteers. It studies immune cells called γδ T cells.

Életkor
18 Years to 80 Years
Nem
All sexes
A betegség stádiuma
Three groups. Healthy volunteers with no acute or chronic major disease. ICU patients who are critically ill without sepsis by the Sepsis-3 criteria. ICU patients who meet the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).
Korábbi kezelés
People cannot join if they had T-cell-targeted immune-suppressing treatment before ICU admission or within 24 hours after it. Examples: antithymocyte globulin, calcineurin inhibitors, mycophenolate mofetil, methotrexate, or corticosteroids >1 mg/kg/day prednisone equivalent. Also immune checkpoint inhibitors (anti-PD-1/PD-L1/CTLA-4) within the past 6 weeks.

A részvétel fő kizáró okai

  • Known immune deficiency, HIV infection or active blood cancer
  • Stem cell or solid organ transplant within the past 3 months
  • Expected ICU stay < 24 hours or very close to death
  • Pregnancy or breastfeeding
  • Active major bleeding

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • Healthy Control Group (NHC):; Age ≥ 18 years; No acute or chronic major diseases; Provide written informed consent
  • Non-septic Critical Illness Group (CI-NS):; Age ≥ 18 years; Admitted to the ICU and meeting the definition of critical illness; Excluded from sepsis according to the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points); Written informed consent provided by the participant or legally authorized representative
  • Septic Critical Illness Group (CI-Sep):; Age ≥ 18 years; Admitted to the ICU and meeting the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points); Written informed consent provided by the participant or legally authorized representative

Ki nem vehet részt

  • Receipt of T-cell-targeted immunosuppressive therapy (e.g., antithymocyte globulin, calcineurin inhibitors, mycophenolate mofetil, methotrexate, or high-dose corticosteroids >1 mg/kg/day prednisone equivalent) before ICU admission or within 24 hours after ICU admission
  • Use of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1/CTLA-4 antibodies) within the past 6 weeks
  • Known immunodeficiency, HIV infection, active hematologic malignancy, or history of hematopoietic stem cell or solid organ transplantation within the past 3 months
  • Active major bleeding
  • Age < 18 years
  • Expected ICU stay < 24 hours or imminent risk of death (moribund state)
  • Pregnancy or breastfeeding
  • Inability to obtain informed consent

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This prospective observational cohort study investigates the subset-specific metabolic adaptation and functional remodeling of cytotoxic γδ T cells in critically ill patients with and without sepsis. As a bridge between innate and adaptive immunity, γδ T cells contribute to early antimicrobial defense; however, their cytotoxic function and its metabolic regulation in sepsis remain incompletely understood. Our preliminary single-cell transcriptomic analysis revealed altered expression of cytotoxicity-associated genes (GZMB, PRF1, and GNLY) and mitochondrial oxidative phosphorylation (OXPHOS) pathway genes in cytotoxic γδ T cells from patients with sepsis. In particular, COX6C expression correlated with cytotoxic effector gene expression. Across healthy volunteers, critically ill non-septic patients, and critically ill septic patients, we will integrate flow cytometry, mitochondrial function assays, and functional validation experiments to characterize circulating cytotoxic γδ T-cell abundance and function and examine the contribution of COX6C to mitochondrial dysfunction and impaired cytotoxicity.

A teljes eredeti leírásKevesebb

To investigate the relationship between systemic tryptophan metabolism and these cellular abnormalities, targeted tryptophan-pathway metabolomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS) will quantify kynurenic acid (KYNA), tryptophan, kynurenine, and related metabolites in paired peripheral blood and fecal samples. Patients with sepsis will be stratified into older (≥65 years) and non-older (<65 years) groups and compared with age-matched healthy volunteers, with critically ill non-septic patients providing an additional disease control group. Metabolite concentrations and pathway-related ratios will be analyzed in relation to cytotoxic γδ T-cell abundance, cytotoxic function, mitochondrial OXPHOS, and COX6C expression, accounting for renal function, disease severity, antibiotic exposure, and nutritional support. These analyses will assess whether age-associated alterations in tryptophan metabolism, particularly KYNA, are associated with cytotoxic γδ T-cell dysfunction and identify candidate metabolic mechanisms for subsequent validation.

A vizsgálat 3 csoportja

  • Healthy Controls (NHCs)

    Healthy volunteers without acute or chronic major diseases, aged ≥18 years, who have provided written informed consent. Participants undergo a single blood draw and rectal swab collection.

  • Critically Ill Non-Septic Patients (CI-NS)

    Patients admitted to the ICU meeting the criteria for critical illness but without sepsis, as determined by the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points excluded). Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative. Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7). Clinical follow-up extends to 90 days.

  • Critically Ill Septic Patients (CI-Sep)

    Patients admitted to the ICU meeting the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points). Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative. Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7). Clinical follow-up extends to 90 days.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Subset-specific Metabolic Adaptation and Functional Remodeling of Gamma Delta T (γδ T) Cells in Critically Ill ICU Patients: A Single-center, Prospective, Observational Cohort Study.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Illeszkedési kérdések
Forrás: NCT07680816: ki vehet részt
A regiszteradat frissítve
2026. október 27.